LeonaBio Reports First Quarter 2026 Financial Results and Provides Business Update

LeonaBio Advances Lasofoxifene Phase 3, Reports Q1 2026 Results

LeonaBio, Inc. reported its first-quarter 2026 financial results and provided key business updates, primarily focusing on the advancement of its lead programs. The company is progressing its Phase 3 ELAINE-3 clinical trial for lasofoxifene, a novel SERM, in patients with ESR1-mutated metastatic breast cancer, expecting to complete enrollment by Q4 2026 and release topline data in H2 2027. Concurrently, LeonaBio is on track to initiate a Phase 2 proof-of-concept study for ATH-1105 in amyotrophic lateral sclerosis (ALS) patients in H2 2026, building on positive Phase 1 data. Financially, the company reported $67.7 million in cash, cash equivalents, and investments as of March 31, 2026, following a $90 million financing in December 2025, with potential for an additional $146 million from warrants.

• LeonaBio is actively advancing its pivotal Phase 3 ELAINE-3 trial (NCT05696626) for lasofoxifene in combination with abemaciclib. This trial targets ER-positive, HER2-negative, ESR1-mutated metastatic breast cancer patients who have progressed on prior endocrine therapies. The company has amended the protocol to increase the sample size to up to 600 participants to ensure sufficient progression events, with enrollment expected to conclude in Q4 2026 and topline data anticipated in H2 2027. The primary endpoint is progression-free survival (PFS) by BICR.
• The company is preparing to initiate a Phase 2 proof-of-concept clinical trial for ATH-1105 in amyotrophic lateral sclerosis (ALS) patients during the second half of 2026. This follows encouraging results from a Phase 1 first-in-human trial (NCT06432647) in healthy volunteers, which demonstrated a favorable safety and tolerability profile, dose-proportional pharmacokinetics, and central nervous system penetration. ATH-1105 is designed as a brain-penetrant small molecule to modulate the neurotrophic HGF system.
• LeonaBio strengthened its corporate governance with the appointment of Fred Callori, Natalie Holles, and Peter B. Silverman to its Board of Directors. The company also highlighted its financial stability, reporting $67.7 million in cash, cash equivalents, and investments as of March 31, 2026. This position is bolstered by a $90 million common stock and warrant financing completed in December 2025, which also provides for a potential additional $146 million upon warrant exercise, supporting future development milestones.

The Persistent Challenges in ESR1-Mutated Metastatic Breast Cancer Treatment

Treatment of ESR1-mutated metastatic breast cancer faces multiple interconnected challenges that limit therapeutic efficacy. Despite advances in targeted therapies, endocrine resistance remains the primary obstacle, with ESR1 mutations serving as a key mechanism driving treatment failure. These challenges span from drug delivery limitations to the emergence of resistance to newer therapeutic agents.

• Limited effectiveness of current SERDs: The first-generation SERD fulvestrant has activity against ESR1 mutant tumors but is severely limited by its intramuscular formulation requiring large-volume monthly injections and poor bioavailability that prevents optimal dosing, while two recent oral SERDs failed to achieve primary endpoints of improved progression-free survival

• CDK4/6 inhibitor resistance emergence: CDK4/6 inhibitor resistance has become the main factor restricting clinical benefit in HR+/HER2-negative metastatic breast cancer patients, despite these agents significantly improving outcomes when combined with endocrine therapy, creating an urgent need for post-progression treatment strategies

• ESR1 fusion-related treatment challenges: The recurrent ESR1-CCDC170 fusion occurring in 6-8% of luminal B breast cancers confers worse clinical outcomes after endocrine therapy by binding to HER2/HER3/SRC and activating SRC/PI3K/AKT signaling pathways that promote cancer cell survival under endocrine treatment

• Lack of predictive biomarkers for treatment selection: No predictive markers of response to chemotherapy are clinically useful for making treatment decisions in individual patients, and guidelines for treatment options after CDK4/6 inhibitor progression remain diverse with limited evidence-based guidance

• Mutation-specific therapeutic targeting gaps: Initial clinical trial data demonstrate that tumors without ESR1 mutations are less likely to benefit from SERDs and may still respond to SERMs or AIs, highlighting the critical need for ESR1 mutation testing to guide appropriate treatment selection in clinical practice

ELAINE-3: Designing a New Standard for ESR1-Mutated mBC

The PADA-1 trial represents the primary clinical study specifically designed for ESR1-mutated ER+/HER2- metastatic breast cancer. This randomized, open-label, phase 3 trial monitored patients for emerging ESR1 mutations during first-line therapy and randomized those developing mutations to either continue current treatment or switch to fulvestrant plus palbociclib.

Lasofoxifene's Unique SERM Profile in a Crowded Landscape

Several other selective estrogen receptor modulators (SERMs) are being evaluated for osteoporosis prevention and treatment, sharing the same mechanism of action as lasofoxifene. These trials employ various intervention models ranging from phase II dose-finding studies to large-scale phase III comparative effectiveness trials.

Lasofoxifene: A New Hope for ESR1-Mutated mBC

The ongoing Phase 3 ELAINE-3 clinical trial for lasofoxifene marks a pivotal moment for patients battling ESR1-mutated metastatic breast cancer, a particularly challenging subset of ER+/HER2- disease. These mutations are a well-established driver of acquired resistance to standard endocrine therapies, including aromatase inhibitors and selective estrogen receptor modulators, especially after progression on cyclin-dependent kinase 4/6 inhibitors (CDK4/6i). For these patients, therapeutic options are often limited, highlighting a significant unmet medical need.

Lasofoxifene, a next-generation selective estrogen receptor modulator (SERM), is designed to specifically target the estrogen receptor, even in the presence of ESR1 mutations. Its potential was underscored by the Phase 2 ELAINE 2 trial, where the combination of lasofoxifene and abemaciclib demonstrated encouraging efficacy, including a median progression-free survival of approximately 13 months and a high clinical benefit rate, alongside an acceptable safety profile. The observed reduction in ESR1-mutant circulating tumor DNA further supports its mechanism of action and target engagement.

LeonaBio's commitment to completing enrollment for ELAINE-3 by Q4 2026, with topline data expected in H2 2027, positions lasofoxifene as a potential game-changer. If ELAINE-3 successfully validates the Phase 2 findings and demonstrates a favorable risk-benefit profile compared to the fulvestrant/abemaciclib combination, it could establish a new, much-needed oral treatment paradigm for this resistant patient population. However, the path to market is not without its hurdles. The trial's outcome against an established combination therapy is critical, and broader market adoption will depend on robust efficacy, a manageable safety profile, and effective physician and patient education, given historical challenges with SERM uptake. The competitive landscape is also evolving rapidly with other novel ER-targeted agents in development, necessitating a strong differentiation strategy for lasofoxifene.